Another ADC foray for Bristol Myers Squibb

In another antibody-drug conjugate (ADC) deal for the US pharma major, Bristol Myers Squibb (NYSE: BMY) has acquired privately-held USA and South Korea-based Orum Therapeutics’ ORM-6151 program.

ORM-6151 is a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader that has received the US Food and Drug Administration’s (FDA) clearance for Phase I for the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndromes.

"We believe this agreement with Bristol Myers Squibb, a global leader in cancer with a strong legacy in protein degradation, validates Orum’s unique Dual-Precision Targeted Protein Degradation approach, which we pioneered to improve the therapeutic window and realize the full potential of targeted protein degraders through precision delivery to cancer cells via antibody drug conjugates," said Sung Joo Lee, chief executive of Orum Therapeutics. "We are excited that Bristol Myers Squibb has acquired our ORM-6151 program with proprietary GSPT1 degraders, first-in-class targeted protein degraders with the potential to make an impact for patients with cancer,” he added.